JenKem Technology offers high quality biodegradable polymers and co-polymers. The interest in biodegradable polymers for the medical and pharmaceutical field stems from the need for extended release drug delivery systems; and for degradable medical devices that do not require human intervention for removal from the body. JenKem® PEGs are ideal candidates as a polymeric backbone, as they have already been successfully applied for wound sealing and healing, controlled drug delivery, and tissue engineering

JenKem PEG Products

PEG co-polymers have applications in micelles, micro/nanoparticles, hydrogel formulations for drug encapsulation, controlled or sustained release drug delivery. Synthetic JenKem PEG co-polymers and PEG derivatives offer several advantages over natural biodegradable polymers:

  • Highly hydrophilic
  • Facile introduction of functional groups for drug attachment
  • Production of JenKem PEGs back-integrated to ethylene oxide raw material
  • Predictable lot-to-lot consistency and raw material sourcing
  • No immunogenicity normally associated with natural polymers

Please see below a selection of JenKem® biodegradable PEG copolymers for time release applications, with oligopeptides polyglutamic acid and PLL (PolyL-lysine) [4-15];  PLA (polylactic acid) [1-2]; and PCL (polycaprolactone). Different copolymers, such as PGA (PolyGlycolide), or PLGA (Poly(lactic-co-glycolic acid) PEGs [3], may be available by custom synthesis – please contact us for details.

JenKem Technology provides GMP grade PEG co-polymers and bulk orders via custom synthesis, offering the opportunity to match customers’ special quality requirements. JenKem Technology is capable of development and synthesis of a wide range of GMP PEG co-polymers under ISO 9001 and ISO 13485 certified quality management system, following ICH Q7A guidelines. For inquiries on cGMP production of PEG derivatives please contact us at

For global distribution, please visit link. Click the buttons below to order directly from JenKem Technology:

Poly(Glutamic Acid) PEGs
≥95% M-PEG-GLU2 Methoxy PEG Di-Glutamic Acid (mPEG-PGA)
≥90% M-PEG-GLU3 Methoxy PEG Tri-Glutamic Acid (mPEG-PGA)
Poly(L-lysine) Linear PEGs (Methoxy PEG PLL)
PEG PRODUCT Main peak fraction (wt%) ITEM DESCRIPTION
≥90% PLL20K-G35-PEG2K, PEG-Poly(L-lysine), Poly(L-lysine), Graft Ratio 3.5, PLL MW 20000, PEG MW 2000
PolyLactide Multiarm PEGs (4arm PEG PLA)
≥95% 4ARM-PEG2500-b-PLA2500, 4arm Polyethylene Glycol Polylactide Block Copolymer, PEG MW 2500, PLA MW 2500
PolyLactide Linear PEGs (PLA PEGs)
≥90% MPEG5000-b-PLA2500, Methoxy Polyethylene Glycol Polylactide Block Copolymer, PEG MW 5000, PLA MW 2500
≥90% MPEG5000-b-PLA5000, Methoxy Polyethylene Glycol Polylactide Block Copolymer, PEG MW 5000, PLA MW 5000
PolyLactide Linear PEG Derivatives (PLA PEG Derivatives)
≥90% MAL-PEG5000-b-PLA20K, Maleimide Polyethylene Glycol Polylactide block copolymer, PEG MW 5000, PLA MW 20000, Substitution (Maleimide) ≥ 70%
≥90% MAL-PEG2000-b-PLA2000, Maleimide Polyethylene Glycol Polylactide block copolymer, PEG MW 2000, PLA MW 2000, Substitution (Maleimide) ≥ 70%
PolyCaprolactone Multiarm PEGs (4arm PCL PEGs)
≥95% 4ARM-PEG2500-b-PCL2500, 4arm Polyethylene Glycol Polycaprolactone Block Copolymer, PEG MW 2500, PCL MW 2500
PolyCaprolactone Linear PEGs (Methoxy PEG PCL)
≥90% MPEG2000-b-PCL2000, Methoxy PEG Polycaprolactone Block Copolymer, PEG MW 2000, PCL MW 2000
Poly(Lactide-co-Glycolide) Linear PEGs (Methoxy PEG PLGA)
>90% COOH-PEG5000-b-PLGA5000, Carboxyl Polyethelyene glycol poly (Lactide-co-glycolide) diblock copolymer, PEG MW 5000, PLGA MW 5000
 PEG NHS Products with Cleavable Linker
≥ 95% Methoxy PEG Succinimidyl Succinate is a degradable PEG linker reacting with the amino group of lysine(s) on proteins or other biologics, such as the active ingredients of Adagen®, Pegademase, PEG aspargase, PEG-L-asparaginase, or PEG-adenosine deaminase, and related biosimilars, at pH 7-8, while the ester linkage is cleaved under regular ester cleaving reaction conditions.
≥ 95% Methoxy PEG Succinimidyl Glutarate is a degradable PEG linker that reacts with the amino group of lysine(s) on proteins or other biologics at pH 7-8, while the ester linkage is cleaved under regular ester cleaving reaction conditions.

For more information on degradable/ cleavable JenKem® PEG linkers with various branching and molecular weights for controlled release drug delivery, please click here.


  1. Wang, Y., et al., Dual micelles-loaded gelatin nanofibers and their application in lipopolysaccharide-induced periodontal disease, International journal of nanomedicine, 2019, 14:963.
  2. Richard, M., et al., Active cargo positioning in antiparallel transport networks, bioRxiv, 2019.
  3. Xiong, Q., et al., Facile fabrication of reduction-responsive supramolecular nanoassemblies for co-delivery of doxorubicin and sorafenib towards hepatoma cells, Frontiers in pharmacology, 2018, 9, p.61.
  4. Jin, Q., et al., Edaravone-Encapsulated Agonistic Micelles Rescue Ischemic Brain Tissue by Tuning Blood-Brain Barrier Permeability, Theranostics, 2017, 7(4):884.
  5. Nguyen, F., et al., Enhanced Intratumoral Delivery of SN38 as a Tocopherol Oxyacetate Prodrug Using Nanoparticles in a Neuroblastoma Xenograft Model, Clinical Cancer Research, 2018, p.3811.
  6. Liang, H., et al., Size-Shifting Micelle Nanoclusters Based on a Cross-Linked and pH-Sensitive Framework for Enhanced Tumor Targeting and Deep Penetration Features. ACS applied materials & interfaces, 2016, 8(16):10136-46.
  7. Li, Q., et al., Development of reactive oxygen species (ROS)-responsive nanoplatform for targeted oral cancer therapy. Journal of Materials Chemistry B, 2016.
  8. Schaedel, L., et al., Microtubules self-repair in response to mechanical stress, Nature Mater., 2015, 14(11):1156-63.
  9. Bhajun, R., et al., A statistically inferred microRNA network identifies breast cancer target miR-940 as an actin cytoskeleton regulator, Scientific Reports, 2015, 5, 8336.
  10. Portran, D., et al., Micropatterning Microtubules, Methods in Cell Biology,  Matthieu P, Manuel T (Editors) Academic Press, 2014, 39-51.
  11. Boujemaa-Paterski, R., et al., Directed actin assembly and motility, Methods Enzymol, 2014, 540: 283-300.
  12. Vignaud, T., et al., Polyacrylamide hydrogel micropatterning, Methods Cell Biol, 2014, 120: 93-116.
  13. Reymann, A.-C., et al, Nucleation geometry governs ordered actin networks structures, Nature Materials, 2010, 9, 827-832.
  14. Kiss, A., et al., Nuclear Motility in Glioma Cells Reveals a Cell-Line Dependent Role of Various Cytoskeletal Components, PLoS ONE, 2014, 9(4): e93431.
  15. Portran, D., et al., Quantification of MAP and molecular motor activities on geometrically controlled microtubule networks, Cytoskeleton, 2013, 70: 12–23.
  16. Schiller, H.B., et al., β1-and αv-class integrins cooperate to regulate myosin II during rigidity sensing of fibronectin-based microenvironments, Nature cell biology, 2013, 15.6 : 625-636.
  17. Galland, R., et al., Fabrication of three-dimensional electrical connections by means of directed actin self-organization, Nature materials, 2013, 12.5 : 416-421.
  18. Portran, D., et al., MAP65/Ase1 promote microtubule flexibility, Molecular biology of the cell, 2013, 24(12):1964-73.
  19. Pitaval, A., et al., Cell shape and contractility regulate ciliogenesis in cell cycle–arrested cells, JCB, 2010, 191 (2):303-312.

Founded in 2001 by experts in PEG synthesis and PEGylation, JenKem Technology specializes exclusively in the development and manufacturing of high quality polyethylene glycol (PEG) products and derivatives, and related custom synthesis and PEGylation services. JenKem Technology is ISO 9001 and ISO 13485 certified, and adheres to ICH Q7A guidelines for GMP manufacture. The production of JenKem® PEGs is back-integrated to in-house polymerization from ethylene oxide, enabling facile traceability for regulated customers. JenKem Technology caters to the PEGylation needs of the pharmaceutical, biotechnology, medical device and diagnostics, and emerging chemical specialty markets, from laboratory scale through large commercial scale.